Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
RESEARCH TOOLSreports
Holding CTNM?
Track your performance easily
CTNM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.33 - $22.00
Previous Close$13.65
Volume55.45K
Average Volume (3M)76.90K
Market Cap
$342.84M
Enterprise Value$129.54M
Total Cash (Recent Filing)$213.91M
Total Debt (Recent Filing)$611.00K
Price to Earnings (P/E)―
Beta2.49
Next Earnings
Nov 06, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding25,777,793
10 Day Avg. Volume74,570
30 Day Avg. Volume76,901
Standard Deviation0.11
R-Squared0.14
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.67
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit2.59
Enterprise Value/Ebitda-6.94
Forecast
1Y Price Target
$29.25Price Target Upside103.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Contineum Therapeutics, Inc. Class A News
PremiumCompany Announcements
Contineum Therapeutics Announces Corporate Presentation UpdatesPremiumCompany Announcements
Contineum Therapeutics Welcomes Sarah Boyce to BoardOptions Prices
Currently, No data available
---
Ownership Overview
3.73% Insiders
7.95% Mutual Funds
51.40% Other Institutional Investors
33.14% Public Companies and
Individual Investors
CTNM FAQ
What was Contineum Therapeutics, Inc. Class A’s price range in the past 12 months?
Contineum Therapeutics, Inc. Class A lowest stock price was $12.33 and its highest was $22.00 in the past 12 months.
What is Contineum Therapeutics, Inc. Class A’s market cap?
Currently, no data Available
When is Contineum Therapeutics, Inc. Class A’s upcoming earnings report date?
Contineum Therapeutics, Inc. Class A’s upcoming earnings report date is Nov 06, 2024 which is 16 days ago.
How were Contineum Therapeutics, Inc. Class A’s earnings last quarter?
Contineum Therapeutics, Inc. Class A released its earnings results on Aug 13, 2024. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.348 by -$0.042.
Is Contineum Therapeutics, Inc. Class A overvalued?
According to Wall Street analysts Contineum Therapeutics, Inc. Class A’s price is currently Undervalued.
Does Contineum Therapeutics, Inc. Class A pay dividends?
Contineum Therapeutics, Inc. Class A does not currently pay dividends.
What is Contineum Therapeutics, Inc. Class A’s EPS estimate?
Contineum Therapeutics, Inc. Class A’s EPS estimate is -$0.41.
How many shares outstanding does Contineum Therapeutics, Inc. Class A have?
Contineum Therapeutics, Inc. Class A has 19,048,620 shares outstanding.
What happened to Contineum Therapeutics, Inc. Class A’s price movement after its last earnings report?
Contineum Therapeutics, Inc. Class A reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.348. Following the earnings report the stock price went up 7.599%.
Which hedge fund is a major shareholder of Contineum Therapeutics, Inc. Class A?
Among the largest hedge funds holding Contineum Therapeutics, Inc. Class A’s share is Perceptive Advisors LLC. It holds Contineum Therapeutics, Inc. Class A’s shares valued at 29M.
---
Contineum Therapeutics, Inc. Class A Stock Smart Score
Company Description
Contineum Therapeutics, Inc. Class A
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
---
CTNM Stock 12 Month Forecast
Average Price Target
$29.25
▲(103.97% Upside)
Technical Analysis
Best Analysts Covering CTNM
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-14.52%
reiterated a buy rating 16 days ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -14.52% per trade.
---